These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27036367)

  • 1. Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity.
    Rouleau L; Antony AN; Bisetto S; Newberg A; Doria C; Levine M; Monti DA; Hoek JB
    Free Radic Biol Med; 2016 Jun; 95():308-322. PubMed ID: 27036367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J; Liu Y; Meng L; Ji B; Yang D
    Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
    Turcios L; Vilchez V; Acosta LF; Poyil P; Butterfield DA; Mitov M; Marti F; Gedaly R
    Dig Liver Dis; 2017 Jun; 49(6):697-704. PubMed ID: 28179093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
    Ha TY; Hwang S; Hong HN; Choi YI; Yoon SY; Won YJ; Song GW; Kim N; Tak E; Ryoo BY
    Anticancer Res; 2015 Apr; 35(4):1985-95. PubMed ID: 25862851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
    Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
    Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.
    Prieto-Domínguez N; Ordóñez R; Fernández A; Méndez-Blanco C; Baulies A; Garcia-Ruiz C; Fernández-Checa JC; Mauriz JL; González-Gallego J
    J Pineal Res; 2016 Oct; 61(3):396-407. PubMed ID: 27484637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
    Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma.
    Cheng Y; Luo R; Zheng H; Wang B; Liu Y; Liu D; Chen J; Xu W; Li A; Zhu Y
    Oncotarget; 2017 Apr; 8(14):23265-23276. PubMed ID: 28423574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
    Nojiri K; Sugimoto K; Shiraki K; Tameda M; Inagaki Y; Ogura S; Kasai C; Kusagawa S; Yoneda M; Yamamoto N; Takei Y; Nobori T; Ito M
    Int J Oncol; 2013 Jan; 42(1):101-8. PubMed ID: 23123700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma.
    Yin X; Xiao Y; Han L; Zhang B; Wang T; Su Z; Zhang N
    AAPS PharmSciTech; 2018 Jul; 19(5):2133-2143. PubMed ID: 29714002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.
    Yao W; Ba Q; Li X; Li H; Zhang S; Yuan Y; Wang F; Duan X; Li J; Zhang W; Wang H
    EBioMedicine; 2017 Aug; 22():58-67. PubMed ID: 28754304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study.
    Abdelmageed MM; El-Naga RN; El-Demerdash E; Elmazar MM
    Sci Rep; 2016 Sep; 6():32733. PubMed ID: 27612096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
    Liu Y; Lou G; Norton JT; Wang C; Kandela I; Tang S; Shank NI; Gupta P; Huang M; Avram MJ; Green R; Mazar A; Appella D; Chen Z; Huang S
    FASEB J; 2017 Dec; 31(12):5453-5465. PubMed ID: 28821631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
    Zhang Y; Zhang B; Zhang A; Zhao Y; Zhao J; Liu J; Gao J; Fang D; Rao Z
    Clinics (Sao Paulo); 2012 Sep; 67(9):1093-9. PubMed ID: 23018309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
    Ishijima N; Kanki K; Shimizu H; Shiota G
    Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Eltrombopag antitumor effect on hepatocellular carcinoma.
    Kurokawa T; Murata S; Zheng YW; Iwasaki K; Kohno K; Fukunaga K; Ohkohchi N
    Int J Oncol; 2015 Nov; 47(5):1696-702. PubMed ID: 26397763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
    Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
    J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
    Tsai JJ; Hsu FT; Pan PJ; Chen CW; Kuo YC
    Anticancer Res; 2018 Apr; 38(4):2119-2125. PubMed ID: 29599330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.